Risk of cardiovascular events and cyclooxygenase-2 inhibitors

Risk of Cardiovascular Events and Cyclooxygenase-2 Inhibitors

Risk of cardiovascular events and cyclooxygenase-2 inhibitors Selective cyclooxygenase-2 (Cox-2) inhibitors have been at the centre of public attention since the revelation that the use of these drugs is associated with an increased risk of cardiovascular events (Tabrizchi 2005). Certainly pharmaco vigilance has an important place in the public domain and any new therapeutic information that le...

Cyclooxygenase-2 inhibitors and cardiovascular thromboembolic events.

iate discriminant analysis did not select V5 or V6 as leads in which ST-segment shift distinguished patients with acute LMCA obstruction from patients with acute obstruction of the left anterior descending coronary artery (LAD). Therefore, we do not consider ST-segment depression in leads V5 and V6 to be a characteristic finding in “LMCA AMI patients.” The findings of our patients indicated tha...

Do cyclooxygenase inhibitors increase risk of cardiovascular thrombotic events?

Cyclooxygenase-2 inhibition and cardiovascular events.

The Promise Introduction of selective cyclooxygenase (COX)-2 inhibitors held a promise of improved treatment of arthritis without the gastrointestinal effects associated with aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs), which effect both COX-1 and COX-2 activity. Celecoxib, etodolac, meloxicam, and rofecoxib are classified as selective COX-2 inhibitors. Initial placebo and l...

COX - 2 Inhibitors and the Risk of Cardiovascular Events

JMAJ, July /August 2006 — Vol. 49, No. 7 •8 *1 Department of Health Chemistry, School of Pharmaceutical Sciences, Showa University, Tokyo Correspondence to: Shuntaro Hara PhD, Ichiro Kudo PhD, Department of Health Chemistry, School of Pharmaceutical Sciences, Showa University, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8555, Japan. Tel: 81-3-3784-8196, Fax: 81-3-3784-8245, E-mail: [email protected]...